{
    "clinical_study": {
        "@rank": "144515", 
        "acronym": "TRACTS", 
        "arm_group": [
            {
                "arm_group_label": "Erlotinib & secondary brain radiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression."
            }, 
            {
                "arm_group_label": "Erlotinib & concurrent brain radiotherapy", 
                "arm_group_type": "Other", 
                "description": "Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons"
            }
        ], 
        "brief_summary": {
            "textblock": "This project is aim to explore non-increased-intracranial-pressure symptomatic brain\n      metastases of NSCLC, and if the OS of secondary brain radiotherapy after recurrence with\n      Erlotinib is better than Erlotinib with concurrent brain radiotherapy. Treatment group are\n      treated with Erlotinib until brain tumor progression, then gave brain radiotherapy, and\n      continued to take Erlotinib till extracranial lesions progression. Control group are\n      Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after\n      radiotherapy until recurrence or termination for other reasons."
        }, 
        "brief_title": "Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small-cell Lung Cancer", 
            "Brain Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Recurrence", 
                "Brain Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Over the age of 18 years old;\n\n          2. Tissue or cell pathological diagnosis of NSCLC;\n\n          3. Brain CT or MR validated BM;\n\n          4. Non-increased-intracranial-pressure symptomatic BM;\n\n          5. Haven't received TKI target treatment;\n\n          6. Haven't received brain radiotherapy;\n\n          7. Patients in initial treatment should be detected EGFR mutation;\n\n          8. Expected survival more than 6 months;\n\n          9. KPS no less than 70, or KPS less than 70 caused by paralysis due to recent brain\n             metastases;\n\n         10. Liver and kidney function requirements: SGOT/SGPT\u22662.5 times of the upper limit, Total\n             bilirubin\u22661.5 times of the upper limit, serum Creatinine\u22661.5 times of the upper\n             limit;\n\n         11. Routine blood test requirements: WBC\u22673.0\u00d7109/L, NE\u22671.8\u00d7109/L, PLT\u226790\u00d7109/L\uff0cno\n             requirement for Hb;\n\n         12. Blood glucose requirements: within the normal range, diabetic patients are receiving\n             treatment and their glucose was being controlled in a steady state;\n\n         13. Female patients in childbearing age: HCG (-);\n\n         14. Patients signed an inform Consent.\n\n        Exclusion Criteria:\n\n          1. Those with Erlotinib drug allergies;\n\n          2. Those with mathematical understanding of the most simple life questions, such as\n             \"walking\", those difficult for doctors to communicate;\n\n          3. Those without guardians or families;\n\n          4. Those with abnormal routine blood test, liver and kidney function, and blood glucose\n             beyond the above boundaries and difficult to correcting for more than 2 weeks;\n\n          5. Those with any unstable medical status (including active infection, uncontrolled\n             hypertension, unstable angina, congestive heart failure, myocardial infarction\n             (within one year before treatment initiation), and severe arrhythmia, liver, kidney\n             or metabolic disease requiring drug therapy);\n\n          6. Those with any other disease, neurological or metabolic dysfunction, and physical\n             examination or laboratory test results showed that the study drugs may increase the\n             risk of treatment-related complications;\n\n          7. Pregnant women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763385", 
            "org_study_id": "2012-75-634"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Erlotinib & secondary brain radiotherapy", 
                    "Erlotinib & concurrent brain radiotherapy"
                ], 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Erlotinib & concurrent brain radiotherapy", 
                "intervention_name": "concurrent brain radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Erlotinib & secondary brain radiotherapy", 
                "intervention_name": "secondary brain radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Erlotinib", 
            "brain radiotherapy", 
            "NSCLC", 
            "brain metastases"
        ], 
        "lastchanged_date": "May 24, 2013", 
        "location": {
            "contact": {
                "email": "yanghj_1@hotmail.com", 
                "last_name": "Huanjun Yang, Master", 
                "phone": "+86-21-64175590", 
                "phone_ext": "6723"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases: A Prospective Multicenter Trial(TRACTS)", 
        "overall_contact": {
            "email": "yanghj_1@hotmail.com", 
            "last_name": "Huanjun Yang, Master", 
            "phone": "+86-21-64175590", 
            "phone_ext": "6723"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Huanjun Yang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "3.5year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763385"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Yang Huan Jun", 
            "investigator_title": "Fudan University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Wu Jieping Medical Foundation", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Changhai Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shanghai Pulmonary Hospital, Shanghai, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Longhua Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "RenJi Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shanghai Armed Police Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shanghai Chest Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shanghai Changzheng Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Wu Jieping Medical Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}